Skip to main content

Advertisement

SpringerLink
Log in

Capn4 promotes non-small cell lung cancer progression via upregulation of matrix metalloproteinase 2

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The expression of calpain small subunit 1 (Capn4) is correlated with the invasion of several types of tumors. However, the roles of Capn4 in non-small cell lung cancer (NSCLC) remain unclear. In this study, we found that the expression of Capn4 in NSCLC tissues was much higher than that in nontumorous samples. High levels of Capn4 expression were associated with lymph node metastasis and large tumor size in NSCLC patients. The 5-year overall survival rate in the Capn4high group was significantly lower than that in the Capn4low group. In multivariate analysis, Capn4 was identified as an independent prognostic factor for overall survival. Moreover, in an in vitro analysis, downregulation of Capn4 expression by siRNA suppressed the invasive potential of lung cancer cells. Finally, we demonstrated that Capn4 enhanced the invasion ability of lung cancer cells by upregulating the expression of matrix metalloproteinase 2. Our findings indicated that Capn4 may represent a potential therapeutic target and a novel prognostic marker of NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.

    Article  PubMed  Google Scholar 

  2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.

    Article  CAS  PubMed  Google Scholar 

  3. Hanna RA, Campbell RL, Davies PL. Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin. Nature. 2008;456(7220):409–12.

    Article  CAS  PubMed  Google Scholar 

  4. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev. 2003;83(3):731–801.

    Article  CAS  PubMed  Google Scholar 

  5. Franco SJ, Huttenlocher A. Regulating cell migration: calpains make the cut. J Cell Sci. 2005;118(Pt 17):3829–38.

    Article  CAS  PubMed  Google Scholar 

  6. Storr SJ, Carragher NO, Frame MC, Parr T, Martin SG. The calpain system and cancer. Nat Rev Cancer. 2011;11(5):364–74.

    Article  CAS  PubMed  Google Scholar 

  7. Lee SJ, Choi YL, Lee EJ, Kim BG, Bae DS, Ahn GH, et al. Increased expression of calpain 6 in uterine sarcomas and carcinosarcomas: an immunohistochemical analysis. Int J Gynecol Cancer. 2007;17(1):248–53.

    Article  PubMed  Google Scholar 

  8. Mamoune A, Luo JH, Lauffenburger DA, Wells A. Calpain-2 as a target for limiting prostate cancer invasion. Cancer Res. 2003;63(15):4632–40.

    CAS  PubMed  Google Scholar 

  9. Bai DS, Dai Z, Zhou J, Liu YK, Qiu SJ, Tan CJ, et al. Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. Hepatology. 2009;49(2):460–70.

    Article  CAS  PubMed  Google Scholar 

  10. Zhang C, Bai DS, Huang XY, Shi GM, Ke AW, Yang LX, et al. Prognostic significance of Capn4 overexpression in intrahepatic cholangiocarcinoma. PLoS One. 2013;8(1):e54619.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Zhuang Q, Qian X, Cao Y, Fan M, Xu X, He X. Capn4 mRNA level is correlated with tumour progression and clinical outcome in clear cell renal cell carcinoma. J Int Med Res. 2014;42(2):282–91.

    Article  PubMed  Google Scholar 

  12. Cai JJ, Qi ZX, Hua W, Zhu JJ, Zhang X, Yao Y, et al. Increased expression of Capn4 is associated with the malignancy of human glioma. CNS Neurosci Ther. 2014;20(6):521–7.

    Article  CAS  PubMed  Google Scholar 

  13. Shimada M, Greer PA, McMahon AP, Bouxsein ML, Schipani E. In vivo targeted deletion of calpain small subunit, Capn4, in cells of the osteoblast lineage impairs cell proliferation, differentiation, and bone formation. J Biol Chem. 2008;283(30):21002–10.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Arthur JS, Elce JS, Hegadorn C, Williams K, Greer PA. Disruption of the murine calpain small subunit gene, Capn4: calpain is essential for embryonic development but not for cell growth and division. Mol Cell Biol. 2000;20(12):4474–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Gu J, Ding JY, Lu CL, Lin ZW, Chu YW, Zhao GY, et al. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer. 2013;81(2):259–65.

    Article  PubMed  Google Scholar 

  16. Zhao GY, Ding JY, Lu CL, Lin ZW, Guo J. The overexpression of 14-3-3zeta and Hsp27 promotes non-small cell lung cancer progression. Cancer. 2014;120(5):652–63.

    Article  CAS  PubMed  Google Scholar 

  17. Dai Z, Zhou SL, Zhou ZJ, Bai DS, Xu XY, Fu XT, et al. Capn4 contributes to tumour growth and metastasis of hepatocellular carcinoma by activation of the FAK-Src signalling pathways. J Pathol. 2014;234(3):316–28.

    Article  CAS  PubMed  Google Scholar 

  18. Zheng PC, Chen X, Zhu HW, Zheng W, Mao LH, Lin C, et al. Capn4 is a marker of poor clinical outcomes and promotes nasopharyngeal carcinoma metastasis via nuclear factor-kappaB-induced matrix metalloproteinase 2 expression. Cancer Sci. 2014;105(6):630–8.

    Article  CAS  PubMed  Google Scholar 

  19. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.

    Article  PubMed  Google Scholar 

  20. Dourdin N, Bhatt AK, Dutt P, Greer PA, Arthur JS, Elce JS, et al. Reduced cell migration and disruption of the actin cytoskeleton in calpain-deficient embryonic fibroblasts. J Biol Chem. 2001;276(51):48382–8.

    CAS  PubMed  Google Scholar 

  21. Cataldo F, Peche LY, Klaric E, Brancolini C, Myers MP, Demarchi F, et al. CAPNS1 regulates USP1 stability and maintenance of genome integrity. Mol Cell Biol. 2013;33(12):2485–96.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Duffy MJ, McCarthy K. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review). Int J Oncol. 1998;12(6):1343–8.

    CAS  PubMed  Google Scholar 

  23. Yadav L, Puri N, Rastogi V, Satpute P, Ahmad R, Kaur G. Matrix metalloproteinases and cancer-roles in threat and therapy. Asian Pac J Cancer Prev. 2014;15(3):1085–91.

    Article  PubMed  Google Scholar 

  24. Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y, et al. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest. 2010;28(6):661–9.

    Article  PubMed  Google Scholar 

  25. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.

    Article  CAS  PubMed  Google Scholar 

  26. Ke AW, Shi GM, Zhou J, Huang XY, Shi YH, Ding ZB et al. CD151 amplifies signaling by integrin alpha6beta1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology. 2011;140(5):1629–41 e15.

  27. Kim MA, Lee HS, Lee HE, Kim JH, Yang HK, Kim WH. Prognostic importance of epithelial-mesenchymal transition-related protein expression in gastric carcinoma. Histopathology. 2009;54(4):442–51.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Science Foundation (Nos. 81372313, 81201834, and 81401876)

Conflict of interest

None.

Author information

Author notes

    Authors and Affiliations

    1. Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China

      Jie Gu, Feng-kai Xu, Guang-yin Zhao, Chun-lai Lu, Zong-wu Lin, Jian-yong Ding & Di Ge

    Authors
    1. Jie Gu
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Feng-kai Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Guang-yin Zhao
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Chun-lai Lu
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Zong-wu Lin
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Jian-yong Ding
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Di Ge
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Jian-yong Ding or Di Ge.

    Additional information

    Jie Gu and Feng-kai Xu contributed equally to this work.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    Supplementary material 1 (DOC 13 kb)

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Gu, J., Xu, Fk., Zhao, Gy. et al. Capn4 promotes non-small cell lung cancer progression via upregulation of matrix metalloproteinase 2. Med Oncol 32, 51 (2015). https://doi.org/10.1007/s12032-015-0500-7

    Download citation

    • Received:

    • Accepted:

    • Published:

    • DOI: https://doi.org/10.1007/s12032-015-0500-7

    Keywords

    Search

    Navigation